| Literature DB >> 27343976 |
Ross Carson1, A Paula Monaghan-Nichols2, Donald B DeFranco3, Anthony C Rudine4.
Abstract
Glucocorticoids (GCs) regulate distinct physiological processes in the developing fetus, in particular accelerating organ maturation that enables the fetus to survive outside the womb. In preterm birth, the developing fetus does not receive sufficient exposure to endogenous GCs in utero for proper organ development predisposing the neonate to complications including intraventricular hemorrhage, respiratory distress syndrome (RDS) and necrotizing enterocolitis (NEC). Synthetic GCs (sGCs) have proven useful in the prevention of these complications since they are able to promote the rapid maturation of underdeveloped organs present in the fetus. While these drugs have proven to be clinically effective in the prevention of IVH, RDS and NEC, they may also trigger adverse developmental side effects. This review will examine the current clinical use of antenatal sGC therapy in preterm birth, their placental metabolism, and their effects on the developing brain. Published by Elsevier Inc.Entities:
Keywords: Antenatal; Glucocorticoids; Neurodevelopment; Preterm birth
Mesh:
Substances:
Year: 2016 PMID: 27343976 PMCID: PMC5052110 DOI: 10.1016/j.steroids.2016.05.012
Source DB: PubMed Journal: Steroids ISSN: 0039-128X Impact factor: 2.668